Fabrice Andre mainly investigates Internal medicine, Breast cancer, Oncology, Cancer and Cancer research. His Internal medicine research focuses on Surgery and how it relates to Disease, Gastroenterology and Intensive care medicine. His Breast cancer research incorporates themes from Chemotherapy regimen and Metastasis.
His study in Oncology is interdisciplinary in nature, drawing from both Chemotherapy, Tumor-infiltrating lymphocytes, Retrospective cohort study, Pathology and Triple-negative breast cancer. His work carried out in the field of Cancer brings together such families of science as Clinical trial and Bioinformatics. His Cancer research research also works with subjects such as
Fabrice Andre spends much of his time researching Internal medicine, Oncology, Breast cancer, Cancer and Cancer research. His Internal medicine study typically links adjacent topics like Pathology. His Oncology course of study focuses on Fulvestrant and Palbociclib.
In Breast cancer, Fabrice Andre works on issues like Bioinformatics, which are connected to Targeted therapy. Fabrice Andre combines subjects such as Clinical endpoint and Pharmacology with his study of Cancer. Fabrice Andre has researched Cancer research in several fields, including Cancer cell, Immunology, Immune system and PI3K/AKT/mTOR pathway.
Internal medicine, Oncology, Breast cancer, Cancer and Cancer research are his primary areas of study. His research integrates issues of Pembrolizumab, Open label, Clinical trial and Triple-negative breast cancer in his study of Oncology. The concepts of his Clinical trial study are interwoven with issues in Precision medicine and Immune system.
His Breast cancer research integrates issues from Odds ratio, Weight loss, Hazard ratio, Prospective cohort study and Cohort. In general Cancer, his work in Fulvestrant and Advanced breast is often linked to Patient-reported outcome and Effective management linking many areas of study. His Cancer research research is multidisciplinary, incorporating elements of PI3K/AKT/mTOR pathway, Antibody, Drug resistance and Osimertinib.
Fabrice Andre focuses on Internal medicine, Breast cancer, Oncology, Cancer and Cancer research. His work in the fields of Adverse effect, Cohort and Clinical endpoint overlaps with other areas such as Clinical Practice. When carried out as part of a general Breast cancer research project, his work on Metastatic breast cancer is frequently linked to work in Educational resources, therefore connecting diverse disciplines of study.
His Oncology research incorporates themes from Pembrolizumab, Clinical trial, Chemotherapy, Predictive biomarker and Triple-negative breast cancer. His research investigates the connection with Cancer and areas like Disease which intersect with concerns in Ensemble learning, Medical imaging and Intensive care unit. His Cancer research research is multidisciplinary, relying on both Receptor, Human leukocyte antigen, Hormone receptor and Locus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Cornelia Liedtke;Chafika Mazouni;Kenneth R. Hess;Fabrice André.
Journal of Clinical Oncology (2008)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Michel Obeid;Michel Obeid;Michel Obeid.
Nature Medicine (2007)
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Ken A. Olaussen;Ariane Dunant;Pierre Fouret;Elisabeth Brambilla.
The New England Journal of Medicine (2006)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
François Ghiringhelli;Lionel Apetoh;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Laetitia Aymeric;Laetitia Aymeric;Laetitia Aymeric.
Nature Medicine (2009)
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi.
The New England Journal of Medicine (2015)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap.
The New England Journal of Medicine (2016)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso;A. Costa;E. Senkus;M. Aapro.
Annals of Oncology (2017)
Malignant effusions and immunogenic tumour-derived exosomes
Fabrice Andre;Noel E C Schartz;Mojgan Movassagh;Caroline Flament.
The Lancet (2002)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert;Gunter von Minckwitz;Jan C. Brase;Bruno V. Sinn.
Journal of Clinical Oncology (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: